Trials / Completed
CompletedNCT00237172
Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 72 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 20 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
This is a extension study of CSTI571B1201 study
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Imatinib Mesylate | once daily |
Timeline
- Start date
- 2002-09-01
- Primary completion
- 2005-07-01
- First posted
- 2005-10-12
- Last updated
- 2012-05-01
Source: ClinicalTrials.gov record NCT00237172. Inclusion in this directory is not an endorsement.